Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
This article was originally published in The Pink Sheet Daily
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.
You may also be interested in...
Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.
Gilead Science Executive VP Gregg Alton defended Sovaldi’s pricing at an AEI event July 11, the same day Senators Wyden and Grassley sent a letter requesting detailed information on the company’s investment in the drug and how it set the price.
The company expects to come charging out of the gate with a three-drug combo therapy for hepatitis C now that it has acquired a nucleotide analog to round out its portfolio. Merck is undeterred by the risks associated with the deal.